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Clostridium difficile Associated Disease (CDAD) 
Rivka H. Borger 
	
Abstract	
Clostridium	 difficile	 bacteria	 (C.	 difficile)	 are	 a	 spore-forming	 species	 of	 bacteria	 that	 lies	
dormant	in	the	colon,	in	the	presence	of	normal	intestinal	flora.		Due	to	overuse	of	certain	antibiotics,	
normal	 intestinal	 bacteria	 may	 be	 depleted,	 and	 combined	 with	 other	
possible	 risk	 factors,	 	 allow	 C.	 difficile	 bacterial	 spores	 to	 develop	 into	
active,	 infectious,	and	extremely	 resistant	 toxin-producing	bacteria.	 	The	
toxins	cause	severe	damage	and	 inflammation	to	the	 intestinal	wall	 that	
can	 result	 in	gastrointestinal	discomfort	and	severe	pseudomembranous	




Clostridium	 difficile	 bacteria	 (C.	 difficile)	 are	 a	 spore-forming	
species	of	bacteria	that	 lie	dormant	in	the	human	colon,	 in	the	presence	
of	normal	intestinal	flora.		It	is	a	commensal	bacterium	in	a	minority	of	the	population.		Smaller	numbers	
do	 not	 develop	 into	 significant	 disease.	 	 (Nation	Master	 Encyclopedia,	 2005)	Most	 commonly	 due	 to	
overuse	 of	 certain	 antibiotics,	 normal	 intestinal	 bacteria	 may	 be	 depleted,	 and	 through	 nutrient	
competition,	allow	C.	difficile	bacterial	spores	to	develop	into	active,	infectious,	and	extremely	resistant	







	 Clostridium	 difficile	 is	 a	 Gram-positive	 anaerobic	 rod-shaped	 bacterium	 (Kunkel,	 2006).	 	 The	
species	was	named	 ‘difficile’	because	 it	was	 initially	hard	 to	 culture	 (Schroeder,	MD,	American	Family	
Physician,	 2005).	 	 It	 belongs	 to	 the	 Clostridiaceae	 Family	 and	 genus	 Clostridium,	 which	 form	 spores.		
They	are	motile	bacteria	that	are	numerous	through	nature,	particularly	soil.		Clostridium	show	optimal	
growth	 at	 human	 body	 temperatures,	 but	 can	 exist	 under	 stress	 in	 the	 more	 tolerant	 spore	 form.	
(Nation	Master	Encyclopedia,	2005).		The	spores	are	resilient	and	resistant	to	high	temperatures.			Early	
studies	 demonstrated	 that	 C.	 difficile	 could	 be	 isolated	 from	 the	 gastrointestinal	 tracts	 of	 most	
neonates,	identifying	it	as	a	commensal	organism	(Schroeder,		2005).		It	is	found	as	part	of	the	normal	
Figure 1 –Endoscopic 
view of classic C difficile–
associated 
pseudomembranous 








Clostridium	 difficile	 produce	 at	 least	 two	 exotoxins:	 an	 enterotoxin	 (Toxin	 A)	 and	 a	 cytotoxin	
(Toxin	B).	 	They	can	kill	cells	by	altering	the	apical	membrane	permeability	of	 the	mucosal	cells	of	 the	
intestinal	 wall,	 and	 are	 subsequently	 responsible	 for	 severe	 inflammation	 possibly	 leading	 to	
enterocolitis	 (Gerding	 et	 al,	 1995).	 Another	 toxin,	 binary	 toxin,	 has	 been	 identified	 without	 a	 role	 in	
CDAD	infection.		(Nation	Master	Encyclopedia,	2005)	
C.	 difficile	 can	 be	 passed	 through	 fecal	 matter	 and	 spores	 can	 lie	 almost	 anywhere	 in	 the	
environment.			
Clostridium	 difficile	 is	 considered	 a	member	 of	 infant	 intestinal	 flora	 as	 up	 to	 50%	 of	 infants	
carry	asymptomatic	C.	difficile	in	their	intestinal	tracts.		It	can	grow	to	high	numbers	with	elevated	toxin	
production	 with	 no	 harmful	 effects	 to	
infants.		(Bongaerts	and	Lyerly,		1996)	
The	 normal	 intestinal	 flora	
under	 typical	 conditions	 keep	 the	
spores	 of	 C.	 difficile	 inactive	 by	
outnumbering	 them	 in	strength.	 	Upon	
depletion	of	normal	 flora,	 the	dormant	
inactive	 spores	 develop	 into	 active,	
infectious,	 and	 resistant	 bacteria	 –	
replacing	 the	 lost	 bacteria	 due	 to	
imbalance	(Merck	Manual,	2006)		
More	 recently,	 C.	 difficile	
infections	 are	more	 rampant	 –	 severe,	
extremely	 resistant,	 and	 easily	
recurrable.	 	 (Kelly	 and	 LaMont,	 2008).		
It	 is	 the	 most	 frequent	 etiologic	 basis	
for	 healthcare-associated	 diarrhea	 and	
a	 common	 cause	 of	 antibiotic-




Additionally,	 two	studies	have	proven	C.	difficile	 to	be	the	most	 frequent	cause	of	nosocomial	
diarrhea.	 	Multiple	 studies	 demonstrate	 the	 link	 between	C.	 difficile	 and	 noscomial	 infection	 –	many	
cases	arise	from	contamination	of	hospital	environment	(Gerding,	et	al,		1995).	
Figure 2 –Scanning electron microscopy of Clostridium 
difficile bacteria specimen,  obtained from human intestine 
(Wiggs, University of Waikato, 2007) 
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ingested	 infect	 the	 patient.		
Spores	can	survive	 the	 low	pH	of	
the	 gastrointestinal	 tract	 and	
survive	 well	 in	 the	 anaerobic	
environment	 of	 the	 large	
intestine,	 allowing	 for	
germination.	 	 Upon	 depletion	 of	
normal	 intestinal	 flora,	C.	difficile	
spores	 no	 longer	 have	 to	




	Antibiotic	overuse	 is	 the	most	 common	 form	of	 intestinal	 flora	depletion.	 	 The	 inactive	 spore	
from	of	C.	difficile,	once	held	in	check	by	nutrient	competition,	becomes	the	dominant	intestinal	species.		
It	is	transformed	to	its	infectious	form,	producing	toxins	that	inflame	and	damage	the	intestinal	mucosa.			
Inflammation	 results	 in	 hyperleukocytosis,	 influxing	 towards	 the	 colon.	 	 Colitis	 is	 variable	 in	
degree,	 from	 mild	 to	 extremely	 severe.	 	 In	 pseudomembranous	 colitis,	 a	 more	 severe	 form,	 toxins	
destroy	 the	 tissue	 of	 the	 intestinal	 epithelia	 until	 the	 tissue	 falls	 off,	 mixes	 with	 leukocytes	 in	 pus	






(Center	 for	Disease	Control,	2008).	 	 Infection	used	to	be	 limited	to	elderly	hospitalized	 individuals	but	
has	grown	rampant	more	recently.		(DeNoon,	2006).			
Figure 3 – 
Scanning electron microscopy of Clostridium difficile bacteria spreading on 
a surface 




	 After	 colonic	 colonization,	 C.	 difficile	 bacteria	 carry	 out	 metabolic	 activities	 similar	 to	 other	
anaerobic	 organisms.	 	 The	 bacteria	 use	 some	 monosaccharides	 (i.e.	 glucose,	 fructose,	 mannitol,	
mannose,	 and	 xylitol),	 but	 not	 disaccharides	 (i.e.	 lactose	 or	 sucrose),	 oligosaccharides,	 or	
polysaccharides	 (i.e.	 starch).	 	 C.	 difficile	 uses	 substances	 not	 found	 free	 in	 nature,	 such	 as	 N-acetyl-
glucosamine	 and	 N-acetyl-neuraminic	 acid,	 by	 using	 extracellular	 hydrolytic	 enzymes	 to	 degrade	
substrates	for	nutrition.	 	 It	can	then	obtain	carbohydrates,	amino	acids,	and	related	nutrients	allowing	
the	 bacteria	 to	 thrive	 in	 the	 intestine.	 	With	 the	 depletion	 of	 normal	 flora,	 there	 are	more	 nutrients	
available	for	the	bacteria	to	thrive	on.		Additionally,	when	a	large	amount	of	resident	intestinal	bacteria	
are	destroyed,	 it	allows	Clostridium	difficile	exposure	to	previously	hidden	sites	of	 the	 intestine.	 	They	
can	 be	 then	 used	 for	microcolony	 formation	 or	 receptor	 sites	 for	 toxins	 in	 toxigenic	 strains.	 	 	 As	 the	
organism	grows,	it	becomes	harder	for	normal	flora	to	replace	it	since	the	bacteria	produces	inhibitory	
metabolic	 products,	 such	 as	 p-cresol,	 ammonia,	 and	 isocaproic	 acid	 –	 all	 inhibiting	 growth	 of	 normal	
flora,	and	disturbing	intestinal	epithelial	cell	membrane	function.	(Bongaerts	and	Lyerly,		1997)	
Pathogenic	strains	of	Clostridium	difficile	cause	enterocolitis	primarily	through	the	production	of	
toxin	A	 (enterotoxin)	 and	 toxin	 B	 (cytotoxin).	 Both	 toxins	 are	 capable	 of	 stimulating	 proinflammatory	
cytokine	production	implicated	in	pseudomembranous	colitis	infection.		Toxins	act	by	altering	regulation	
of	 cytoskeletal	 protein,	 leading	 to	 cell	 rounding	 and	 cell	 death.	 	 (Hull	 and	 Beck,	 College	 of	 Family	
Physicians	 of	 Canada,	 2004)	 	 The	 toxins	 cause	 leukocyte	 chemotaxis	 and	 the	 upregulations	 of	
inflammatory	mediators	such	as	cytokines,	producing	colonic	inflammation.		Clinical	evidence	would	be	
a	 significantly	 elevated	white	blood	 cell	 count,	 correlating	 to	presence	of	 infection.	 	 Focal	 ulcerations	
occur	with	increasing	severity	of	colitis,	and	necrotic	tissue	form	a	membrane-like	material.	 	Thus,	 it	 is	
Figure 4 – The Potent Effects on Toxin B vs. Toxin A on Intestinal Epithelium 
(A) Control, treated with buffer alone – no toxins.  (B) treated with 32 nM of toxin A for 5 hours.  (C) and (D) 
treated with 3 nM of toxin B for 5 hours. 
(B) Exposure to toxin A shows disruptions of superficial epithelium with crypt epithelium intact.  (C) treatment 
with toxin B shows disruption of superficial epithelium as well.  (D) shows higher magnification of colonic 
damage wrought by toxin B. 










than	 does	 toxin	A.	 	 In	 this	 experiment,	 human	 intestinal	mucosa	was	 exposed	 to	 varying	 amounts	 of	
both	Clostridium	difficile	toxins	A	and	B	for	five	hours	and	subsequent	damage	was	observed.		Significant	
damage	was	observed	afterward,	both	electrophysiologically	and	morphologically.	 	Both	toxins	caused	








an	hour	 incubation	with	 an	 enteric	microorganism	 such	 as	Escherichia	 coli.	 	 Effects	 of	 toxins	A	 and	B	





possibly	 affect	 its	 potency	 such	 as	 fimbriae	 (enabling	 bacterial	 adherence)	 and	 glycocalyx	
(antiphagocytic	 capsule),	 both	 of	 which	 are	 produced	 in	 greater	 numbers	 in	 toxigenic	 strains	 of	 C.	
difficile.	 	 Some	highly	virulent	 strains	produce	elevated	protease	 levels,	 linked	among	other	 clostridial	
pathogens	 to	 increased	 virulence.	 	 Other	 extracellular	 hydrolytic	 enzymes	 may	 play	 a	 similar	 role	
(Bongaerts	and	Lyerly,	1997).			
C.	 difficile	 bacteria	 can	 also	 have	 specific	 antibiotic-resistant	 genes,	 targeting	 specific	
antimicrobial	agents	through	unique	bacterial	physiology	and	biochemistry.	 	An	example	of	this	would	
be	the	ermB	gene,	encoding	a	23S	ribosomal	methylase	that	causes	resistance	to	macrolide-lincosamide-




Another	 strain	 of	 Clostridium	 difficile	 bacteria	 has	 been	 identified	 relatively	 recently,	 named	
North	 American	 pulsed-field	 gel	 electrophoresis	 type	 1	 (NAP	 1),	 causing	 several	 outbreaks	 in	 North	
America	 and	 Europe.	 	 It	 is	 resistant	 to	 both	 gatifloxacin	 and	 moxifloxacin	 antibiotics	 (both	 of	 the	
fluoroquinolone	antibiotic	group),	unlike	other	strains	previously	designated.			NAP	1	produces	16	times	
greater	 toxin	A	and	23	 times	greater	 toxin	B	 than	other	 strains	do,	possibly	 related	 to	a	deletion	 in	a	
negative	 regulatory	 gene.	 	 It	 also	 produces	 a	 third	 toxin,	 binary	 toxin,	 whose	 purpose	 has	 not	 been	
deemed	 significant	 yet.	 	 (Sunenshine	 and	 McDonald,	 	 2006).	 This	 new	 strain	 has	 become	 the	 more	
dominant	strain,	due	to	the	high	rate	of	mutation.		It	is	highly	virulent	and	has	raised	C.	difficile-related	
death	 rates	 by	 35%	 yearly	 (DeNoon	 and	 Chang,	 2008).	 	 Additionally,	 resistance	 to	 fluoroquinolone	






antimicrobial	 therapy,	 more	 prevalent	 in	
certain	antibiotic	groups.					
Antimicrobial	 agents	 that	 target	
anaerobic	 bacteria	 are	 potentially	more	 lethal,	
possibly	because	 they	alter	 intestinal	 flora	and	
microbial	ecology.		(Gerding	et	al,	1995)	
	 Almost	 all	 antimicrobial	 agents	 except	
for	 aminoglycosides	 are	 associated	 with	
Clostridium	 difficile	 infection	 (Sunenshine	 and	
McDonald,	Cleveland	Clinic	Journal	of	Medicine,	
2006).	 Clindamycin	 has	 been	 identified	 as	 a	
targeting	 agent,	 confirmed	 by	 ermB	 gene	 isolation,	 encoding	 methylase	 enzyme	 causing	 antibiotic	
resistance	 to	 lancosamides	 (Clindamycin	 belonging	 to	 that	 family).	 (Hull	 and	 Beck,	 College	 of	 Family	
Physicians	of	Canada,	2005).	Other	common	high-risk	antibiotics	are	broad	spectrum	penicillins,	second	
and	 third	 generation	 cephalosporins,	 erythromycin,	 sulfonamides,	 chloramphenicol,	 tetracycline,	 and	
fluoroquinolones.	 	 Fluoroquinolones	 in	 particular	were	 isolated	 in	 a	 cohort	 study	 as	 the	 predominant	
risk	factor	for	CDAD	in	a	specific	epidemic	in	Quebec	2003-4	(Pepin	et	al,	2005).				It	is	most	commonly	
due	 to	 oral	 antibiotics	 but	 can	 also	 occur	 due	 to	 intravenous	 or	 intramuscular	 antibiotics.	 (Merck	
Manual,	2006).		Other	antimicrobial	agents,	including	antiviral	and	antifungal	drugs	increase	the	risk	as	
well	(Mayo	Clinic	2006).	Risk	more	than	doubles	with	greater	than	three	days	of	antimicrobial	therapy.			
Reduced-risk	 antibiotics	 include	 vancomycin,	 metronidazole,	 and	 antipseudomonals.		
(Schroeder,		2005).			 		
Figure 5– marked exudates protruding through 
mucosal ulcerations 





Other	 drugs	 may	 increase	 susceptibility	 as	 well,	 such	 as	 drugs	 and	 conditions	 that	 decrease	
gastric	 acidity.	 	Over	 the	 counter	 antacids	 and	proton	pump	 inhibitors	 such	as	 aciphex,	 prevacid,	 and	
related	 drugs	would	 put	 a	 patient	 at	 higher	 risk	 (Merck	Manual,	 2006).	 	 Proton	 pump	 inhibitor	 (PPI)	
utilization	 is	 associated	 with	 upper	 gastrointestinal	 tract	 colonization	 and	 altering	 of	 intestinal	 flora.		
Decreased	 gastric	 acidity	 is	 a	 known	 risk	 factor	 for	 infectious	 diarrheal	 illnesses.	 	 Since	 Clostridium	
difficile	bacteria	thrive	on	higher	gastric	pH	levels,	decreased	gastric	acidity	may	also	pose	a	risk	factor	
for	 CDAD.	 This	 is	 supported	 by	 CDAD	 cases	 reported	 from	 patients	 receiving	 Helicobactor	 pylori	
treatment	–	 combining	proton	pump	 inhibitors	with	antibiotics.	 	A	 study	comparing	 rate	of	C.	difficile	
infection	in	patients	undergoing	gastric	acid	suppressive	therapy	with	those	who	did	not,	with	PPI	usage	
increasing	the	risk	significantly.	(Dial	et	al,	CMAJ,	2004).		Two	case-controlled	studies	conducted	over	ten	
years	 showed	 the	 increase	 in	 rate	 of	Clostridium	 difficile	 infection	 due	 to	 PPI	 usage	 and	H2	 blockers.		
(Dial,	et	al,	JAMA,	2005).	




organisms	 is	 highly	 prevalent	 via	 the	 hands	 of	 health-care	workers	 and	 is	 considered	 the	most	 likely	
mechanism.		(Centers	for	Disease	Control	and	Prevention	(CDC)	2007).			
Other	risk	factors	 include	underlying	 illness,	weakened	 immune	system,	recent	hospitalization,	
residency	 in	 long-term	 care	 facilities,	 recent	 surgery	 –	 primarily	 abdominal/gastrointestinal,	 chronic	
colon	disease	such	as	inflammatory	bowel	disease	or	colon	cancer.		Additionally,	previous	infection	with	
Clostridium	 difficile	 increases	 patient	 susceptibility	 to	 reinfection.	 	 (Mayo	 Clinic,	 2006).	 	 	 Highest	 risk	
patients	are	those	with	recent	immunosuppressive	therapy	or	recent	surgical	procedures,	partly	due	to	
patients’	 inability	to	generate	IgG	antibody	immune	response	against	Clostridium	difficile	toxin	A.	 	 	 IgG	







clinical	 symptoms	even	 though	 they	would	 test	positive	 for	C.	difficile	organism	and/or	 toxins.	 	Other	




														Common	 symptoms	 for	Clostridium	difficile	 infection	 are	watery	 diarrhea	 (characterized	 by	 at	
least	 three	 bowel	 movements	 daily	 for	 more	 than	 two	 days	 but	 usually	 ten	 or	 more),	 abdominal	
cramping	and	tenderness,	nausea,	loss	of	appetite,	and	fever	of	up	to	104	–	105	degrees	F.			(Centers	for	
Disease	Control	and	Prevention,	2004).	 	 It	 is	also	possible	to	have	an	abnormal	heartbeat	(Healthwise,	
2006).	 	Other	 symptoms	 include	blood	or	pus	 in	 the	 stool,	dehydration,	and	weight	 loss	 (Mayo	Clinic,	





several	 weeks	 after	 completing	 all	 antibiotics.	 	 This	 was	 evidenced	 in	 a	 study	 of	 cancer	 outpatients	
diagnosed	with	CDAD	where	the	median	interval	(range	2-60	days)	from	discharge	to	infection	was	20.3	
days	–	a	3	week	delay	(Sunenshine	and	McDonald,		2006).		




weeks	 but	 usually	 improve	without	 treatment	 (EMIS	 and	 PIP,	 2007).	 	 Systemic	 symptoms	 are	 usually	
 
Figure 6 – 
Pathogenesis of 









(Sunenshine	 and	McDonald,	 2006).	 	 They	may	 also	 include	 low	 grade	 leukocytosis	 and	 tenesmus	 –	 a	
sudden	urge	to	evacuate	the	rectum	(Hull	and	Beck,	2004).			
Moderate	 infectious	symptoms	include	leukemoid	reaction	–	a	stress	response	to	disease	with	
an	 increased	 leukocyte	count	of	approximately	50.0	x109/L,	 fever,	dehydration,	nausea,	 vomiting,	and	
abdominal	tenderness.	Hull	and	Beck,	2004).			
The	 severest	 cases	 present	 with	 dehydration	 and	 electrolyte	 disturbance,	 severe	 bloody	
diarrhea,	fever,	and	abdominal	pain	and	cramping	(EMIS	and	PIP,	2007).	It	may	lead	to	sepsis	and	shock,	
acidosis	 (increased	 acidity	 of	 blood	 plasma),	 tachycardia,	 multisystem	 organ	 failure	 including	 kidney	





may	 actually	 lead	 to	 a	 decrease	 in	 diarrheal	 episodes.	 	 (Sunenshine	 and	 McDonald,	 2006).	 	 Toxic	
megacolon	 is	 rare	 but	 has	 been	 documented	 in	 several	 cases,	 leading	 to	 a	mortality	 rate	 of	 33%	 for	




usage,	 abdominal	 pain,	 diarrhea,	 and	 related	 symptoms.	 	 Doctors	 may	 still	 test	 without	 presence	 of	
diarrhea	 since	 in	 rare	 instances	C.	difficile	 bacteria	 can	 cause	abdominal	pain	and	 tenderness	without	
diarrhea	(MedicineNet,	2008).		C.	difficile	is	also	suspected	when	diarrhea	develops	during	or	soon	after	
hospitalization	(EMIS	and	PIP,	2007).				
Figure 7 – (L) Image of normal cecum  
(R) Image of pseudomembranes formed from Clostridium difficile overgrowth of 
cecum.   
(Adapted from  Johnson, Medical Microbiology,  2009) 
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Treating	 without	 diagnostic	 laboratory	 basis	 is	 not	 indicated,	 especially	 since	 only	 30%	 of	
hospitalized	patients	with	diarrhea	have	CDAD,	even	during	epidemics.			There	are	some	exceptions	for	
which	 empiric	 therapy	 would	 be	 necessary	 –	 including	 severely	 ill	 or	 rapidly	 deteriorating	 high-risk	
patients	(Sunenshine	and	McDonald,	2006).		
												Patients	 with	 CDAD	 often	 have	 leukocytosis	 with	 strong	 elevation	 in	 severe	 enterocolitis.		
Physicians	 may	 screen	 leukocyte	 count	 as	 well	 as	 for	 white	 blood	 cell	 presence	 in	 the	 stool.		
Confirmation	 of	 those	 two	 tests	 proves	 positive	 for	 colitis	 and	would	 need	more	 testing	 to	 diagnose	
CDAD	 (MedicineNet,	 2008).	 	 	 Stool	 leukocyte	 measurement	 may	 have	 limited	 diagnostic	 accuracy	
(Nation	Master	Encyclopedia,	2005).			A	sudden	rise	in	the	leukocyte	count	to	between	30-50x109/L	cells	
combined	 with	 severe	 bandemia	 (immature	 white	 blood	 cells)	 is	 an	 indicator	 of	 fulminant	 colitis.		




can	 also	 cause	 false-positives	 due	 to	 the	 available	 non-
toxigenic	strains.	 It	must	grow	48-96	hours	anaerobically	
for	 proper	 results.	 	 (Centers	 for	 Disease	 Control	 and	
Prevention	 (CDC),	 2005).	 	 It	 has	 an	 overall	 sensitivity	 of	
95%	 but	 has	 a	 low	 specificity,	 necessitating	 toxicity	
testing	 (Canadian	 Paediatric	 Society,	 Paediatrics	 &	 Child	
Health,	 2000).	 	 	 It	 is	 not	 specific	 for	 pathogenic	 toxin-
producing	 strains	 of	 Clostridium	 difficile	 and	 is	 not	 as	
clinically	 helpful	 (Schroeder,	 American	 Family	 Physician,	
2005).	 	 It	 is	 the	 least	 chosen	 method	 of	 testing	 in	
hospitals	 due	 to	 cost	 and	 length	 of	 procedure.	 	 It	 does	
however	have	an	advantage	of	lending	itself	to	molecular	
typing	 of	 strains,	 useful	 in	 a	 C.	 difficile	 outbreak	
(Sunenshine	and	McDonald,	2006).	
Antigen	 detection	 for	 C.	 difficile	 are	 rapid	 tests	
completed	in	less	than	an	hour,	used	to	detect	presence	of	C.	difficile	antigen	by	latex	agglutination	or	
immunochromatographicassays.	 	 It	 must	 be	 combined	 with	 toxin	 testing	 for	 diagnostic	 confirmation	
(Centers	for	Disease	Control	and	Prevention	(CDC),	2005).		
Toxin	testing	includes	both	enzyme	immunoassay	and	tissue	culture	cytotoxicity.			
Enzyme	 immunoassay	detects	 toxins	A,	B,	or	both	 together.	 	 It	uses	monoclonal	antibodies	 to	
detect	toxin	(Hull	and	Beck,	2004).		Assay	is	completed	same-day	but	is	less	sensitive	than	tissue	culture	
cytotoxicity	 assay	 (Centers	 for	 Disease	 Control	 and	 Prevention	 (CDC),	 2005).	 	 Enzyme-linked	
Immunoabsorbant	Assay	(ELISA)	has	a	sensitivity	rate	of	63-99%	and	a	specificity	of	93-100%.	 	Experts	
recommend	 sending	 as	many	as	 3	 samples	 to	 rule	out	disease	 if	 patients	 receive	negative	 result,	 but	
Figure 8 – anaerobic culture of 
Clostridium difficile bacteria on 
Cycloserin-Cefoxitin Fructose Agar 
(Anaerobe Systems, CA)  
(Adapted from  Johnson, Medical 
Microbiology,  2009) 
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2000).	 	 Latex	agglutination-based	assays	 recognize	enzyme	glutamate	dehydrogenase	but	do	not	have	
sensitivity	 (Hull	 and	 Beck,	 2004).	 	 Polymerase	 chain	 reaction	 (PCR)	 detects	 toxigenic	 C.	 difficile.		
Amplification	 of	 a	 gene	 portion	 of	 either	 toxin	 A,	 toxin	 B,	 or	 a	 combination	 of	 the	 two	 genes	 is	
performed.	 	PCR	can	be	conducted	on	the	specimen	organisms	for	presence	of	toxins	that	match	with	
the	 reading	 of	 the	 known	 toxins.	 	 One	 testing	 conducted	 (Kato	 et	 al)	 amplified	 only	 toxin	 A	 from	C.	
difficile.		Others	had	similar	or	less	success.		It	is	not	as	sensitive	as	other	testing	methods	(Gerding	et	al,	
1995).		
Colon	 examination	 is	 used	 to	 confirm	 diagnosis	 of	 Clostridium	 difficile.	 	 Patients	 undergo	
sigmoidoscopy	or	colonoscopy	to	screen	for	presence	




when	 clinical	 suspicion	 is	 high	 despite	 negative	
results.	 	 Colonoscopy	 can	 detect	 more	 than	 a	
sigmoidoscopy	 since	 it	 examines	 the	 whole	 colon	
where	C.	difficile	can	encompass,	rather	than	just	the	
sigmoid	colon	(Hull	and	Beck,	2004).			
Imaging	 tests	 such	 as	 CT	 scans	 provide	
detailed	 images	 of	 the	 colon.	 	 Scans	 can	 show	
thickening	 of	 the	 colon	 wall,	 common	 in	
22	
	
pseudomembranous	 colitis	 (Mayo	 Clinic,	 2006).	 	 In	 conjunction	 with	 the	 clinical	 history,	 presence	 of	
ascites,	colon	wall	thickening,	or	dilation	can	predict	severity	of	enterocolitis	(Schroeder,	2005).														
Treatment	





necessary	 cause	 of	 treatment	 (EMIS	 and	 PIP,	 2007).	 	 CDAD	 typically	 resolves	 in	 23%	 of	 cases	 upon	
removal	from	the	antimicrobial	treatment	(Centers	for	Disease	Control	and	Prevention	(CDC),	2005).			




In	 a	 study	 of	 189	 patients	 with	 CDAD,	 97%	 responded	 to	 initial	 antibiotic	 therapy	 (Sunenshine	 and	
McDonald,	Cleveland	Clinic	Journal	of	Medicine,	2006).		Symptoms	should	subside	within	2-3	days.		The	
antibiotics	can	also	prevent	perforation	of	the	colon	if	treated	in	time	(EMIS	and	PIP,	2007).		Drugs	are	
usually	 effective	 with	 few	 side	 effects	 (Centers	 for	 Disease	 Control	 and	 Prevention	 (CDC),	 2007).	 	 In	




choose	Vancomycin	primarily	for	severe	colitis	since	 it	can	achieve	higher	antibiotic	 levels	 in	the	colon	
and	 can	 theoretically	 be	 more	 effective	 at	 eradicating	 bacteria	 there	 with	 more	 area	 specificity	
(MedicineNet,	 2008).	 	 	 It	 can,	 however,	 contribute	 to	 the	 growth	 of	 antibiotic-resistant	 bacteria.		
Metranidazole	can	not	be	used	for	women	who	are	pregnant	or	breastfeeding.		Both	antibiotics	kill	only	
the	active	infectious	form	of	C.	difficile,	not	the	tougher	spores.		Since	spores	are	resistant	and	remain	in	
the	body,	 infection	 can	 return,	 requiring	 further	 treatment	 (Mayo	Clinic,	 2006).	 	 	 For	 those	unable	 to	




and	 it	 should	be	 treated	 as	 a	 secondary	 agent	 in	 treatment.	 	 Colestipol	 is	 even	 lower	 than	Bacitracin	
(Gerding	et	al,	1995).		
	 Some	 physicians	 prescribe	 supplementary	 probiotics	 to	 restore	 normal	 intestinal	 flora.	 	 A	




Antidiarrheal	 medications	 such	 as	 loperamide,	 diphenoxylate,	 and	 bismuth	 compounds	 are	
contraindicated	and	can	worsen	 the	course	of	pseudomembranous	colitis.	 	 Slowing	of	 fecal	 transit	 tie	
can	 possibly	 extend	 toxin-associated	 damage.	 	 Cholestyramine,	 usually	 used	 to	 lower	 cholesterol,	 is	
more	 effective	 in	 slowing	bowel	motility	without	 causing	more	damage	 (Nation	Master	 Encyclopedia,	
2005).		
	If	the	disease	causes	fulminant	colitis,	surgical	resection	of	the	colon	may	be	needed,	especially	
with	 colon	 perforation	 (EMIS	 and	 PIP,	 2007).	 	 	 In	 e	 cases	 causing	 severe	 pain,	 organ	 failure,	 or	
inflammation	 of	 abdominal	 wall	 lining,	 surgical	 removal	may	 be	 the	 only	 option	 (Mayo	 Clinic,	 2006).			
Surgery	should	be	considered	especially	if	initial	treatment	does	not	resolve	the	disease	and	symptoms	
progress	 rapidly.	 	 Still,	 treatment	 should	 not	 be	 considered	 failure	 before	 6-7	 days	 of	 therapy	
(Sunenshine	and	McDonald,	2006).	 	At	 times,	a	patient	may	 relapse	with	 recurring	episodes	of	CDAD.		
Multiple	courses	of	antibiotics	may	be	needed.	 	Probiotic	 treatment	may	be	helpful	 for	this	 (Canadian	
Paediatric	Society,		2000).		Approximately	15-35%	of	patients	have	recurrent	disease.		This	could	be	from	
reinfection	or	germination	from	residual	spores.		The	most	likely	reason	for	relapse	is	that	C.	difficile	had	
not	 been	 completely	 eradicated	 during	 treatment	 (MedicineNet,	 2008).	 	 	 	 There	 is	 no	 evidence	 that	
recurring	 infections	cause	more	severe	disease	(Hull	and	Beck,	College	of	Family	Physicians	of	Canada,	
2004).	 	 	Another	possible	 reason	 leading	 to	 relapse	 is	 the	body’s	 inadequate	production	of	antibodies	
against	 the	bacterial	 toxins	 (MedicineNet,	2008).	 Fecal	enemas,	however,	 are	difficult	 to	perform	and	
there	is	an	increased	risk	of	transmitting	retroviruses	or	other	infectious	diseases	(Schroeder,	2005).				
	Fecal	 bacteriotherapy,	 sometimes	 commonly	 called	 a	 “stool	 transplant”,	 has	 its	 basis	 in	
probiotic	 therapy	 research.	 	 Normal	 intestinal	 bacterial	 flora	 obtained	 from	 the	 feces	 of	 a	 healthy	
individual	 is	 infused	 through	 the	 intestine	of	 the	patient	 in	 an	 effort	 to	 restore	 normal	 flora	 balance,	
decreasing	the	strength	of	the	C.	difficile	organisms	and	lessen	likelihood	of	recurrence.		This	treatment	
is	usually	used	for	people	with	recurring	episodes	of	disease.		It	has	a	success	rate	of	nearly	95%	(Nation	
Figure 10 – Laboratory preparation of stool for fecal bacteriotherapy  
(The Medical Post, 2009) 
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	 Most	 importantly,	 avoid	 using	 antibiotics	 unless	 absolutely	 necessary.	 	 Antibiotics	 will	 not	
eradicate	 viral	 illnesses,	 yet	 they	 are	 still	 used	 for	 that	 purpose	 several	 times	 annually.	 	 Even	 some	
common	bacterial	ailments	 like	bronchitis	and	ear	 infections	can	be	treated	without	antibiotics	 (Mayo	
Clinic,	 2006).	 	 In	 particular,	 restriction	 of	 Clindamycin	 has	 been	 shown	 to	 decrease	 incident	 of	 CDAD	
(Schroeder,	2005).		
	 If	antibiotics	are	necessary,	have	 the	physician	prescribe	 from	a	narrow-spectrum	range	 to	be	
taken	 in	 the	 shortest	 amount	 of	 time	possible	 for	 least	 likelihood	of	 disrupting	 intestinal	 flora	 (Mayo	
Clinic,	2006).		
	 Use	 probiotic	 supplements	 –	 yogurt	 with	 live	 cultures,	 acidophilus,	 and	 similar	 during	 the	
antibiotic	 course.	 	 However,	 only	 Saccharomyces	 boulardii	 is	 proven	 effective	 against	 C.	 difficile	
specifically	 (Mayo	 Clinic,	 2006).	 	 Lactobacilli	 have	 been	 proven	 effective	 against	 antibiotic-associated	
diarrhea,	but	not	necessarily	that	caused	by	Clostridium	difficile.			
	 Any	patient	with	CDAD,	 even	 asymptomatically	 colonized,	 can	 transmit	 the	disease	 to	others.		
Only	those	on	antibiotics,	hospitalized,	or	with	other	prevailing	risk	factors	are	most	likely	to	get	ill.		To	
reduce	 transmission,	wash	hands	 carefully	especially	after	 restroom	use	and	before	eating.	 	Regularly	


















	 Clostridium	 difficile-Associated	 Disease	 (CDAD)	 may	 be	 a	 slightly	 rare	 disease	 but	 with	
devastating	 effects.	 	Due	 to	depletion	of	 normal	 intestinal	 flora	 in	 conjunction	with	other	 risk	 factors	
including	 immunocompromised	 state	or	 recent	hospitalization,	 dormant	 resistant	 spores	 transform	 to	
virulent	 possibly	 toxigenic	 infectious	 form	 of	 bacteria	 that	 can	 multiply	 rapidly.	 	 Although	 broad	 in	




proper	precautions.	 	 	Should	someone	already	have	the	disease,	proper	care	must	be	 implemented	to	
ensure	 no	 further	 transmission	 as	 spores	 can	 be	 spread	 through	 contact	 and	 fecal-oral	 methods.		
Research	is	still	preliminary	for	other	treatments,	including	vaccination	against	C.	difficile	toxins.			With	
proper	prevention	and	treatment,	and	increase	in	patient	antibodies	to	target	the	organism,	even	in	the	
absence	of	normal	intestinal	flora,	Clostridium	difficile-Associated	Disease	can	be	eradicated.		
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